Download
1 / 84

Family Paramyxoviridae Subfamily Paramyxovirinae: Genes : Morbillivirus – measles virus, - PowerPoint PPT Presentation


  • 141 Views
  • Uploaded on

Family Paramyxoviridae Subfamily Paramyxovirinae: Genes : Morbillivirus – measles virus, Respirovirus (earlier Paramyxovirus) – parainfluenza virus serotypes 1 and 3 Rubulavirus - parainfluenza virus serotypes 2, 4а, 4 b, mumps virus Subfamily Pneumovirinae

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Family Paramyxoviridae Subfamily Paramyxovirinae: Genes : Morbillivirus – measles virus, ' - miyo


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

FamilyParamyxoviridae

SubfamilyParamyxovirinae:

Genes: Morbillivirus – measles virus,

Respirovirus (earlierParamyxovirus) – parainfluenza virusserotypes 1 and 3

Rubulavirus - parainfluenza virusserotypes 2, 4а, 4b, mumps virus

Subfamily Pneumovirinae

Genes: Pneumovirus – RS-virus

Metapneumovirus


Properties of the Paramyxoviruses

A.Structure: The particle has a lipid-containing envelope covered with spikes; a helical ribonucleoprotein nucleocapsid 18 nm in diameter is enclosed. The RNA is a single molecule (MW 5-8 x 106).


Paramyxoviruses
PARAMYXOVIRUSES

pleomorphic

HN/H/G glycoprotein

SPIKES

F glycoprotein

SPIKES

helical nucleocapsid (RNA minus

NP protein)

lipid bilayer membrane

polymerase complex

M protein



The envelope of paramyxoviruses contains 2 glycoproteins, HN and F, that form spikelike projec­tions from the surface of the viral membrane. These glycoproteins are involved in the early interactions between virus and cell. The larger glycoprotein, HN, has neuraminidase and hemagglutinating activities and is responsible for virus adsorption.

The other glycoprotein, F, is involved in virus-induced cell fusion and hemolysis and in virus penetration through fusion of viral and cell membranes. The membrane-fusing activity of Ihe F protein is activated by proteolytic cleavage of a precursor (Fo) by a host enzyme to yield 2 disulfide-linked polypeptides (F1 and F2). Only then can viral replication begin.


HN: Larger virus glycoprotein, responsible both for hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown.


B. Biologic Properties: hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown.

1. Cell fusion. In the course of infection, paramyxoviruses cause cell fusion, long recognized as giant cell formation. This ability to fuse cells is now used for the creation of cell hybrids, an important tool in somatic cell genetics.

2. Persistent infection. Most paramyxoviruses can produce a persistent noncytocidal infection of cultured cells. The clinical importance of this property may explain subacute sclerosing panencephalitis (SSPE).

3. Antigenic properties. Measles, canine distemper, and rinderpest viruses have related antigens. Another antigenically related group includes mumps, parainfluenza, and Newcastle disease viruses.


C. Replication. hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown. The RNA genome of viruses of this group is not infectious and does not function as messenger RNA. Instead, the viral genome is transcribed into shorter RNA molecules that serve as messenger and are complementary to the genome. The paramyxoviruses possess an RNA-dependent RNA polymerase that is a structural component of the virion and produces the initial messenger RNA.


MUMPS (Epidemic Parotitis) hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown.

Mumps is an acute contagious disease characterized by a nonsuppurative enlargement of one or both of the parotid glands, although other organs may also be involved.

Properties of the Virus

Mumps virus is a typical paramyxovirus.

A. Morphology and Biochemical Properties.

The mumps virus particle has the typical paramyxovirus morphology. Typical also are the biologic properties of hemagglutination, neuraminidase, and hemolysin. Hemagglutination can be inhibited by specific antisera to mumps virus, and this inhibition can be used to measure antibody responses. Similarly, the nucleocapsid of the virus particle forms the major component of the "S" (soluble) complement-fixing antigen.


B. Reactions to Physical and Chemical Agents. hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown. The hemagglutinin, the hemolysin, and the infectivity of the virus are destroyed by heating at 56 °C for 20 minutes. The skin test antigen and the complement-fixing antigen are more heat-stable.

C. Animal Susceptibility and Growth of Virus. In monkeys, mumps can produce a disease that is very much like that in human beings. Parotitis is produced by introducing the virus into Stensen's duct or directly into the gland by injection. By the use of fluorescent antibody, the virus has been located in the cytoplasm of acinar cells.

The virus grows readily in embryonated eggs and in cell culture. Passage in embryonated eggs reduces pathogenicity for humans, and this method was used to obtain a vaccine strain. Mumps virus growing in cell culture produces multinucieated giant cells (syncytia).


D. Skin Test. hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown. A skin test antigen for determining hypersensitivity to mumps virus is available, A posi­tive test is considered to be erythema and induration greater than 15 mm 24-48 hours after injection. The skin lest is of uncertain value in predicting immune status, since both false positives and false negatives occur frequently.


Pathogenesis and Pathology hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown.

Two theories exist regarding the pathogenesis of mumps. (1) The virus travels from the mouth by way of Stensen 's duct to the parotid gland, where it undergoes primary multiplication. This is followed by a generalized viremia and localization in testes. ovaries, pancreas, thyroid, or brain. (2) Primary replication occurs in the superficial epithelium of the respiratory tract. This is followed by a generalized viremia and simultaneous localization in the salivary glands and other organs.

Little tissue damage is associated with uncompli­cated mumps. The ducts of the parotid glands show desquamation of the epithelium, and polymorphonuclear cells are present in the lumens. There are interstitial edema and lymphocytic infiltration. With severe orchitis, the testis is congested, and punctate hemorrhage as well as degeneration of the epithelium of the seminiferous tubules is observed. Central nervous sys­tem pathology may vary from perivascular edema to inflammatory reaction, glial reaction, hemorrhage, or demyelination.


Clinical Features hemagglutinatlon and receptor-destroying activities of the virus particle. F: Smaller virus glycoprotein, Involved In cell fusion by these viruses and probably in the entry of the virus Into the cell. F is composed of 2 disulfide bond-linked polypeptides cleaved from a high-molecular-weight precursor. Lipid bilayer: The lipid is cell-derived but probably altered in composition from that of the normal cell. M: Nonglycosylated membrane protein. The HN, F, M, and lipid bilayer can be disrupted, destroying hemolytic activity, and then reassembled without the nucleocapsid, whereupon hemolytic activity is restored. NP: Ribonucleoprotein, the major complement-fixing antigen. There is another small protein of about 47,000 molecular weight whose location and function in the virion are unknown.

The incubation period is commonly 18-21 days. A prodromal period of malaise and anorexia is followed by rapid enlargement of parotid glands as well as other salivary glands. Swelling may be confined to one parotid gland, or one gland may enlarge several days before the other. The gland enlargement is associated with pain, especially when tasting acid sub­stances- The salivary adenitis is commonly accompanied by low-grade fever and lasts for approximately a week.

The testes and ovaries may be affected, especially after puberty. Twenty percent of males over 13 years of age who are infected with mumps virus develop orchitis, which is often unilateral and does not usually lead to sterility. Because of the lack of elasticity of the tunica albuginea, which does not allow the inflamed testis to swell, atrophy of the testis may follow secondary to pressure necrosis. Secondary sterility does not occur in women because the ovary, which has no such limiting membrane, can swell when inflamed.


Mumps accounts for 10-15% of aseptic meningitis observed in the USA and is more common among males than females. Meningoencephalitis usually occurs 5-7 days after the inflammation of the salivary glands, but it may occur simultaneously or in the absence of parotitis and is usually self-limiting. The cerebrospinal fluid shows pleocytosis (10-2000//n,L, mostly lymphocytes) that may persist after clinical recovery.

Rare complications of mumps include (1) a self-limiting polyarthritis that resolves without residual deformity; (2) pancreatitis associated with Transient hyperglycemia, glycosuria, and steatorrhea (it has been suggested that diabetes mellitus may occasionally fol­low); (3) nephritis; (4) thyroiditis; and (5) unilateral nerve deafness (hearing loss is complete and permanent) . Mumps may be a possible causative agent in the production of aqueductal stenosis and hydrocephalus in children. Injection of mumps virus into suckling hamsters has produced similar lesions.


Laboratory Diagnosis the USA and is more common among males than females. Meningoencephalitis usually occurs 5-7 days after the inflammation of the salivary glands, but it may occur simultaneously or in the absence of parotitis and is usually self-limiting. The cerebrospinal fluid shows pleocytosis (10-2000//n,L, mostly lymphocytes) that may persist after clinical recovery.

Laboratory studies are not usually required to establish the diagnosis of typical cases. However, mumps can sometimes be confused with enlargement of the parotids due to suppuration, foreign bodies in the salivary ducts, tumors, etc. In cases without parotitis, particularly in aseptic meningitis, the laboratory can be helpful in establishing the diagnosis.

A. Recovery of Virus: Virus can be isolated from saliva, cerebrospinal fluid, or urine collected within 4 days after onset of illness. After treatment with antibiotics, the specimens are inoculated into monkey kidney cell cultures. Virus growth can be detected in 5-6 days by adsorption of suitable erythrocytes by the infected cells. The isolate can be identified with specific antiserum that can inhibit the hemadsorption. Immunofluorescent serum can also identify a virus isolate in cell culture within 2-3 days.


B. Serology. the USA and is more common among males than females. Meningoencephalitis usually occurs 5-7 days after the inflammation of the salivary glands, but it may occur simultaneously or in the absence of parotitis and is usually self-limiting. The cerebrospinal fluid shows pleocytosis (10-2000//n,L, mostly lymphocytes) that may persist after clinical recovery. Antibody rise can be detected in paired sera. The CF test is best for specificity and accuracy, although the HI test may be used. A 4-fold or greater rise in antibody titer is evidence of mumps infection.

A CF test on a single serum sample obtained soon after onset of illness may serve for a presumptive diagnosis. S (soluble) antibodies develop within a few days after onset and sometimes reach a high titer before V (viral) antibodies can be detected. In early convalescence, both S and V antibodies are present at high levels. Subsequently, S antibodies disappear more rap­idly, leaving V antibodies as a marker of previous infection for several years. The intradermal injection of inactivated virus results in reappearance of V antibodies in high titer. Neutralizing antibodies also appear during convalescence and can be determined in cell culture.


C. Skin Test Antigen: the USA and is more common among males than females. Meningoencephalitis usually occurs 5-7 days after the inflammation of the salivary glands, but it may occur simultaneously or in the absence of parotitis and is usually self-limiting. The cerebrospinal fluid shows pleocytosis (10-2000//n,L, mostly lymphocytes) that may persist after clinical recovery. Delayed type hypersensitivity may be noted about 3-4 weeks after onset. The skin test is less reliable than serologic tests to establish evidence of past infection.

Immunity

Immunity is permanent after a single infection. Only one antigenic type exists. Passive immunity is transferred from mother to offspring; thus it is rare to see mumps in infants under age 6 months.

Treatment

Gamma globulin is of no value for decreasing the incidence of orchitis, even when given immediately after parotitis is first noted.


Epidemiology the USA and is more common among males than females. Meningoencephalitis usually occurs 5-7 days after the inflammation of the salivary glands, but it may occur simultaneously or in the absence of parotitis and is usually self-limiting. The cerebrospinal fluid shows pleocytosis (10-2000//n,L, mostly lymphocytes) that may persist after clinical recovery.

Mumps occurs throughout the world endemically throughout the year. Outbreaks occur where crowding favors dissemination of the virus. The disease reaches its highest incidence in children age 5-15 years, but epidemics occur in army camps. Although morbidity rates are high, the mortality rate is negligible, even when the nervous system is involved.

Humans are the only known reservoir of virus. The virus is transmitted by direct contact, airborne droplets, or fomites contaminated with saliva and, perhaps, urine. The period of communicability is from about 4 days before to about a week after the onset of symptoms. More intimate contact is necessary for the transmission of mumps than for measles or varicella.


About 30-40% of infections with mumps virus are inapparent. Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

Antibodies to mumps virus are transferred across the placenta and are gradually lost during the first year of life. In urban areas, antibodies are then acquired gradually, so that the 15-year-old group has about the same prevalence of persons with antibodies as the adult group. Antibodies are acquired at the same rate by persons living under favorable and unfavorable socio-economic conditions.


Control Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

Mumps is usually a mild childhood disease. A live attenuated vaccine made in chick embryo cell culture is available. It produces a subclinical noncommunicable infection.

The vaccine is recommended for children over age 1 year and for adolescents and adults who have not had mumps parotitis, A single dose of the vaccine given subcutaneously produces detectable antibodies in 95% of vaccinees, and antibody persists for at least 8 years.

Combination live virus vaccines (measles-mumps-rubella) produce antibodies to each of the vi­ruses in about 95%.

In 1967, the year mumps vaccine was licensed, there were about 200,000 mumps cases (and 900 patients with encephalitis) in the USA. After 10 years of vaccine use, the number of mumps cases in 1977 was about 22,000, with 70 cases of encephalitis.


PARAINFLUENZA VIRUS INFECTIONS Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

The parainfluenza viruses are paramyxoviruses with morphologic and biologic properties typical of the genus. They grow welt in primary monkey or human epithelial cell culture but poorly or not at all in the embryonated egg. They produce a minimal cytopathic effect in cell culture but are recognized by the hemad-sorption method. Laboratory diagnosis may be made by the HI, CF, and Nt tests.


Parainfluenzae virus
Parainfluenzae virus Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.


Piv structure
PIV STRUCTURE Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.


Piv transmission through droplet dispersion courtesy american assoc for the adv of science
PIV- transmission through droplet dispersion Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.(Courtesy-American Assoc. for the Adv. Of Science)


Parainfluenza 1 Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

Included here are Sendai virus, also known as the hemagglutinating virus of Japan (HVJ), and hemadsorption virus type 2 (HA-2). Sendai virus may be a causative agent of pneumonia in pigs and newborn infants. Sendai virus is important in somatic cell genetics, where it is used to produce cell fusion. Clinically, the most important member of this group appears to be the widespread HA-2 virus. It is not cytopathogenic for monkey kidney cell cultures but is detected in such cultures by the hemadsorption test. It is one of the main agents producing croup in children, but it can also cause coryza, pharyngitis, bronchitis, bronchiolitis, or pneumonia. In adults it produces respiratory symptoms like those of the common cold, with reinfection occurring in persons with antibodies from earlier infections.

Natural infection stimulates antibody appearance in nasal secretions and concomitant resistance to reinfection, An experimental killed vaccine induces serum antibodies but does not protect against infection


Parainfluenza 2 Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

This group includes the croup-associated (CA) virus of children. The virus grows in human cells (HeLa, lung, amnion) and monkey kidney. Syncytial masses are produced, with loss of cell boundaries. The virus agglutinates chick and human type 0 erythrocytes. Adsorption and hemagglutination occur at 4 °C, and elution of virus takes place rapidly at 37 °C. However, the cells reagglutinate when returned to 4 °C. Mumps patients develop type 2 antibodies.

Parainfluenza virus 2 occurs spontaneously in 30% of lots of monkey kidney cells grown in culture, The monkey virus SV5 is antigenically related.


Parainfluenza 3 Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.

The viruses in this group are also known as hemadsorption virus type 1 (HA-1). They are detected in monkey kidney cultures by the hemadsorption technique. Serial passage in culture may lead to cytopathic changes. Multinucleated giant cell plaques are produced under agar in certain human cell lines.

The virus has been isolated from children with mild respiratory illnesses, croup, bronchiolitis, or pneumonitis. Strains of type 3 virus have been isolated from nasal secretions of cattle ill with a respiratory syndrome known as "shipping fever. At least 70% of market cattle bled at slaughter have parainfluenza 3 antibodies.


Parainfluenza Individuals with subclinical mumps acquire immunity. During the course of inapparent infection, they can serve as sources of infection for others.4 and 5

These viruses are not known to cause any human illness, although antibodies are widespread. Their growth in cell culture can be recognized by the hemad­sorption method.

Clinical Features and Control

Children in the first year of life with primary infections caused by parainfluenza virus type 1, 2, or 3 may have serious illness ranging from laryngo-tracheitis and croup (particularly type 2) to bronchitis, bronchiolitis, and pneumonitis (particularly type 3).


Virtually all infants have maternal antibodies to parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such rein-fections usually present as nonfebrile upper respiratory infections ("colds").

The incubation for type 1 is 5-6 days; that for type 3 is 2-3 days. Most children have acquired an­tibodies to all 3 types before age 10.

Killed parainfluenza vaccines induce serum anti­bodies but no immunity. Live vaccines arc being investigated


Virtually all infants have maternal antibodies to parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such reinfections usually present as nonfebrile upper respiratory infections ("colds").

The incubation for type 1 is 5-6 days; that for type 3 is 2-3 days. Most children have acquired antibodies to all 3 types before age 10.

Killed parainfluenza vaccines induce serum anti­bodies but no immunity. Live vaccines are being investigated


MEASLES (Rubeola) parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such reinfections usually present as nonfebrile upper respiratory infections ("colds").

Measles is an acute, highly infectious disease characterized by a maculopapular rash, fever, and respiratory symptoms.

Properties of the Virus

A. Morphology and Biologic Properties: Measles virus is a typical paramyxovirus, related to canine distemper and bovine rinderpest. All 3 lack neuraminidase activity. Measles agglutinates monkey erythrocytes at 37 °C but does not elute, and it interacts with a distinct cell receptor. Measles virus also causes hemolysis, and this activity can be separated from that of the hemagglutinin.


Measles virus parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such reinfections usually present as nonfebrile upper respiratory infections ("colds").


B. Animal Susceptibility and Growth of Virus: parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such reinfections usually present as nonfebrile upper respiratory infections ("colds").

The experimental disease has been produced in monkeys. They develop fever, catarrh, Koplik's spots, and a discrete papular rash. The virus has been grown in chick embryos; in cell cultures of human, monkey, and dog kidney tissue; and in human continuous cell lines. In cell cultures, multinucleate syncytial giant cells form by fusion of mononucleated ones, and other cells become spindle-shaped in the course of their degeneration. Nuclear changes consist of margination of the chromatin and its replacement centrally with an acidophilic inclusion body. Measles virus is relatively unstable after it is released from cells. During the culture of the virus, the intracellular virus liter is 10 or more times the extracellular liter.


Pathogenesis and Pathology parainfluenza viruses in serum, yet such antibodies do not prevent infection or disease. Reinfection of older children and adults also occurs in the presence of antibodies arising from an earlier infection. Such reinfections usually present as nonfebrile upper respiratory infections ("colds").

The virus enters the respiratory tract, enters cells, and multiplies there. During the prodrome, the virus is present in the blood, throughout the respiratory tract, and in nasopharyngeal, tracheobronchial, and conjunctival secretions. It persists in the blood and nasopharyngeal secretions for 2 days after the appearance of the rash, Transplacental transmission of the virus can occur.

Koplik's spots are vesicles in the mouth formed by focal exudations of serum and endothelial cells, followed by focal necrosis. In the skin the superficial capillaries of the corium are first involved, and it is here that the rash makes its appearance. Generalized lymphoid tissue hyperplasia occurs. Multinucleate giant cells are found in lymph nodes, tonsils, adenoids, spleen, appendix, and skin. In encephalomyelitis, there are petechial hemorrhages, lymphocytic infiltration, and. later, patchy demyelination in the brain and spinal cord.


Measles nucleoprotein antigens have been iden­tified by immunofluorescence within inclusion bodies in nerve cells of the brain in subacute sclerosing panencephalitis (SSPE). The virus has been grown by co-cultivating HeLa cells with brain biopsy material or lymph node material from patients. The presence of latent intracellular measles virus in these specimens suggests a tolerant infection with defective cell-mediated immunity.

If measles antibody is added to cells infected with measles virus, the viral antigens on the cell surface are altered. By expressing fewer viral antigens on the surface, cells may avoid being killed by antibody- or cell-mediated cytotoxic reactions, yet may retain viral genetic information. This may lead to persistent infection as found in SSPE patients.


Clinical Findings immunofluorescence within inclusion bodies in nerve cells of the brain in

The incubation period is about 10 days to onset of fever and 14 days to appearance of rash. The prodromal period is characterized by fever, sneezing, coughing, running nose, redness of eyes, Koplik's spots (enanthems of the buccal mucosa), and lymphopenia. The fever and cough persist until the rash appears and then subside within 1-2 days. The rash spreads over the entire body within 2-4 days, becoming brownish in 5-10 days. Symptoms of the disease are most marked when the rash is at its peak but subside rapidly thereafter.

In measles, the respiratory tract becomes more susceptible to invasion by bacteria, especially hemolytic streptococci; bronchitis, pneumonia, and otitis may follow in 15% of cases.


Encephalomyelitis occurs in about 1:1000 cases. There appears to be no correlation between the severity of the measles and the appearance of neurologic complications. The cause of measles encephalitis is un­known . It has been suggested that early central nervous system involvement is caused by direct viral invasion of the brain. Later appearance of central nervous system symptoms is associated with demyelination and may be an immunopathologic reaction. Symptoms referable to the brain usually appear a few days after the appearance of the rash, often after it has faded. There is a second bout of fever, with drowsiness or convulsions and pleocytosis of the cerebrospinal fluid. Survivors may show permanent mental disorders (psychosis or personality change) or physical disabilities, particularly seizure disorders. The mortality rate in encephalitis associated with measles is about 10-30%, and many survivors (40%) show sequelae.


Measles virus appears to be responsible for sub-acute scterosing panencephalitis (SSPE), a fatal de­generative brain disorder. The disease manifests itself in children and young adults by progressive mental deterioration, myoclonic jerks, and an abnormal dectroencephalogram with periodic high-voltage com­plexes. The disease develops a number of years after the initial measles infection.

Atypical measles. After the introduction of killed measles virus vaccine in 1965, a new clinical syndrome was observed in children who had a history of receiving the vaccine. The syndrome, called atypical measles, was associated with measles virus infection and was characterized by high fever, pneumonia, and an unusual rash (raised papules, wheals, and tiny hemorrhages in the skin) without Koplik's spots. Killed measles virus vaccine is no longer used. Atypical measles is now seen occasionally in young adults.


Laboratory Diagnosis scterosing panencephalitis (SSPE), a fatal de­generative brain disorder. The disease manifests itself in children and young adults by progressive mental deterioration, myoclonic jerks, and an abnormal dectroencephalogram with periodic high-voltage com­plexes. The disease develops a number of years after the initial measles infection.

Measles is usually easily diagnosed on clinical grounds. About 5% of cases lack Koplik's spots and are difficult to differentiate clinically from infection with rubella virus, certain enteroviruses, and adenoviruses.

A. Recoveryof Virus. Measles virus can be isolated from the blood and nasopharynx of a patient from 2-3 days before the onset of symptoms to 1 day after the appearance of rash. Human amnion or kidney cell cultures are best suited for isolation of virus.

B. Serology. Specific neutralizing, hemagglutination-inhibiting, and complement-fixing antibodies develop early, with maximal liters near the time of onset of rash. There is only a gradual decline in anti­body liter with age.

Measles and canine distemper share an antigen. Measles patients develop antibodies that cross-react with canine distemper virus. Similarly, dogs, after infection with distemper virus, develop antibodies that fix complement with measles antigen. Rinderpest virus is also related to measles.


Immunity scterosing panencephalitis (SSPE), a fatal de­generative brain disorder. The disease manifests itself in children and young adults by progressive mental deterioration, myoclonic jerks, and an abnormal dectroencephalogram with periodic high-voltage com­plexes. The disease develops a number of years after the initial measles infection.

There appears to be only one antigenic type of measles virus, as one attack generally confers lifelong immunity. Most so-called second attacks represent errors in diagnosis of the initial or the second illness.


Epidemiology scterosing panencephalitis (SSPE), a fatal de­generative brain disorder. The disease manifests itself in children and young adults by progressive mental deterioration, myoclonic jerks, and an abnormal dectroencephalogram with periodic high-voltage com­plexes. The disease develops a number of years after the initial measles infection.

Measles is endemic throughout the world. In general, epidemics recur regularly every 2-3 years. The state of immunity of the population is the determining factor. The disease flares up when there is an accumulation of susceptible children. By age 20 years, over 80% have had an attack of the disease. The severity of an epidemic is a function of the number of susceptible individuals. Only about 1% of susceptible persons fail to contract measles on their first close contact with a patient.

When the disease is introduced into isolated communities where it has not been endemic, all age groups develop clinical measles. A classic example of this was the introduction of measles into the Faroe Islands in 1846; only people over age 60 years, who had been alive during the last epidemic, escaped the disease. In places where the disease strikes rarely, its consequences are often disastrous, and the mortality rate may be as high as 25%.


The highest incidence of measles is in the late winter and spring. Infection is contracted by inhalation of droplets expelled in sneezing or coughing. Measles is spread chiefly by children during the catarrhal prodromal period; they are infectious from 1-2 days prior to the onset of symptoms until a few days after the rash has appeared.


Control spring. Infection is contracted by inhalation of droplets expelled in sneezing or coughing. Measles is spread chiefly by children during the catarrhal prodromal period; they are infectious from 1-2 days prior to the onset of symptoms until a few days after the rash has appeared.

Live attenuated measles virus vaccine effectively prevents measles. Prior to the introduction of the vaccine, over 500,000 cases of measles occurred annually in the USA, and over 300 developed encephalitis. Following mass immunization in 1966-1967, the number of cases decreased to 67,000 and 22,000 annually in the next 2 years, with a corresponding decrease in measles encephalitis. Nevertheless, measles continues to occur, and in 1976 and 1977, the reported cases increased to 40,000 and 56,000 respectively— 90% among the nonvaccinated. About 95% of children properly inoculated with live virus vaccine develop antibodies that persist for at least 14 years.


As of 1979, an effective measles vaccine has been given to 70% of the children in the USA. The result has been the disappearance of the major epidemics of the 1950s that infected and immunized 98% of children by age 10. However, the 30% of children who were not immunized in the 1960s became the susceptible adolescents of the 1970s. In 1977, one-fourth of measles cases in the USA occurred in persons over 15 years of age. To prevent adult measles from becoming a major problem, the vaccination program for children has been intensified, with the result that measles cases in 1981 decreased to about 3000, a record low, From a prevaccination rate of 400 measles deaths per year, the number in 1980 had dropped to only 6.


Less attenuated vaccine virus may produce fever and a modified skin rash in a proportion of vaccinees; this reaction can be prevented by the simultaneous administration of gamma globulin (0.02 mL/kg body weight) at a separate site from the vaccine. The more attenuated vaccine viruses do not produce symptoms and do not require the use of gamma globulin. The different vaccine viruses appear to be equally effective in producing immunity.

Measles antibodies cross the placenta and protect the infant during the first 6-10 months of life. Vaccination with the live virus fails to take during this period, and measles immunization should be deferred until 15 months of age. This applies both to monovalent measles vaccine and to combined measles-mumps-rubella vaccine.


When the live vaccine was first introduced, it was often given to infants in the first year of life. This did not produce immunity, and such children must be revaccinated.

Vaccination is not recommended in persons with febrile illnesses or allergies to eggs or other products used in the production of the vaccine, and in persons with immune defects.

Epidemiologic studies have shown that the risk, if any, of SSPE occurring in vaccinated persons is much less than the risk of its occurring in persons who have natural measles.


Killed measles vaccine should not be used, as certain vaccinees become sensitized and develop either local reactions when revaccinated with live attenuated virus or severe atypical measles when infected with wild virus or even with live vaccine virus.

Measles may be prevented or modified by administering antibody early in the incubation period. Human gamma globulin contains antibody liters of 200-1000 against 100 TCID50 of virus. With small doses, the disease can be made mild and immunity ensues. With a large dose of gamma globulin, the disease can be prevented; however, the person remains susceptible to infection at a later date. Antibodies given later than 6 days after exposure are not likely to influence the course of the disease.


RESPIRATORY SYNCYTIAL (RS) VIRUS vaccinees become sensitized and develop either local reactions when revaccinated with live attenuated virus or severe atypical measles when infected with wild virus or even with live vaccine virus.

This labile paramyxovirus produces a characteristic syncytial effect, the fusion of cells in human cell culture. It is the single most serious cause of bronchiolitis and pneumonitis in infants.

The particle is slightly smaller (80-120 nm) than other paramyxoviruses, and the nucleocapsid measures 11-15 nm. Although RS is one of the most labile of viruses, it can be stabilized by molar MgSC>4 (like measles and other paramyxoviruses). RS virus does not hemagglutinate.

A soluble complement-fixing antigen can be separated from the virus particle.


Rsv structure
RSV- Structure vaccinees become sensitized and develop either local reactions when revaccinated with live attenuated virus or severe atypical measles when infected with wild virus or even with live vaccine virus.


Rsv syncytium formation

RSV- syncytium formation vaccinees become sensitized and develop either local reactions when revaccinated with live attenuated virus or severe atypical measles when infected with wild virus or even with live vaccine virus.


Rsv syncytium formation1

RSV- syncytium formation vaccinees become sensitized and develop either local reactions when revaccinated with live attenuated virus or severe atypical measles when infected with wild virus or even with live vaccine virus.


RS virus can be grown in cell culture, but it fails to grow in eggs or in laboratory animals. Immunofluorescence can determine the virus antigen in cell culture.

RS virus can be isolated from about 40% of in­fants under age 6 months suffering from bronchiolitis and from about 25% with pneumonitis, but it is almost never isolated from healthy infants. RS virus infection in older infants and children results In milder respiratory tract infection than in those under 6 months of age. Adult volunteers can be reinfected with RS virus (in spite of the presence of specific antibodies), but the resulting symptoms are those of an upper respiratory infection, a "cold."

Recently, RS viral antigen has been found in osteoclasts in bone sections and in cells cultured from Paget's disease lesions.


RS viruse spreads extensively in children every year during the winter season. Reinfection commonly occurs in children, but each subsequent infection is milder than the preceding ones. Nosocomial infections occur in nurseries and on pediatric hospital wards. Transmission occurs primarily via the hands of staff members. Hand washing after every patient contact, wearing gowns and gloves, and isolation of infected patients reduce nosocomial spread.

RS virus grows slowly in cell cultures (4-8 days). For more rapid results, the direct immunofluorescence test with RS antiserum can be applied to nasopharyngeal smears containing exfoliated cells.


Maternal RS antibody is transmitted to the fetus, but it does not protect the infant from disease.

The clinical disease in young infants may actually be the result of an antigen-antibody reaction that results when the infecting virus meets maternally transmitted antibody. Killed RS vaccines may do more harm than good. Efforts to develop an attenuated vaccine that infects subclinically and induces nasal anti­body are in progress.

RS virus occurs spontaneously in chimpanzees and has been associated with coryza in these primates


Rsv bronchiolitis clinical features
RSV Bronchiolitis- clinical features does not protect the infant from disease.


LABORATORY DIAGNOSIS does not protect the infant from disease.

ACUTE RESPIRATORY VIRAL INFECTION

Acute respiratory viral infection (ARVI) is characterized by catarrhal manifestations of various intensity secondary to epithelial damage to the mucosa of the upper respiratory tract, polymorphic clinical manifestations ranging from mild and subclinical forms of the disease to very severe forms with a fatal outcome.

Viruses responsible for the development of ARVI are numerous (over 150) and belong to various taxonomic groups. Most oftenARVIis caused by paramyxoviruses, reoviruses, coronaviruses, rhinoviruses, enteroviruses, and adenoviruses.

The laboratory diagnosis ofARVI is based on rapid diagnostic methods, virological and serological examination.


Diagnosis rsv in hep 2 cell culture immunofluoresent stain
Diagnosis- RSV in Hep-2 cell culture does not protect the infant from disease.(immunofluoresent stain)


  • RSV is a viral disease. does not protect the infant from disease.

  • Respiratory Syncytial Virus (RSV)is a very serious virus often found in children and infants under the age of three.

  • Adults are at very low risk of catching RSV.


How is this disease transmitted? does not protect the infant from disease.

  • This disease is transmitted by:

  • coughing

  • sneezing

  • sharing wash cloths towels and other things with someone with RSV.

  • Most people with RSV get it in fall and winter.


How is this disease transmitted

How is this disease transmitted? does not protect the infant from disease.

How is this disease transmitted?

  • Symptoms for this disease are:

  • sneezing

  • runny nose

  • sore throat

  • low fever

  • common cold symptoms just more severe.


Risk group
Risk Group does not protect the infant from disease.

Risk Group

  • Babies and elders are most at risk of catching RSV.

  • Although adults do catch it, it appears to them as being a common cold.


Is this a serious disease
Is this a serious disease? does not protect the infant from disease.

Is this disease transmitted?

  • This disease is extremely serious when it comes to children and infants under the age of 3 and elders.

  • This disease can result in death.


Treatments for Disease does not protect the infant from disease.

  • The main thing a doctor will tell you if you ask about treatments for RSV he will most likely say to let it run it’s course.Things you can do for the person that has RSV are:

  • comfort that person.

  • Things you can do if you have it are:

  • Drink plenty of fluids.

  • Get lots of rest.


Disease prevention
Disease Prevention does not protect the infant from disease.

Disease Prevention

  • Wash hands before you eat and after you use the bathroom.

  • Don’t share towels or wash cloths with others.

  • Eat healthy.

  • Keep clean.

  • Stay clear of people who are ill.


In diseases induced by paramyxoviruses, respiratory-syncytiai, corona-, reo-, and adenoviruses, one examines washings off the nasal portion of the throat and secretion of the mucous membrane of the posterior portion of the throat, which is removed with several cotton tampons. From one tampon impression smears are made, the remaining ones are immersed in 2-5 ml of Hanks' solution. To in­crease the resistance of paramyxoviruses, 0.5 per cent of gelatin or bovine albumin is added to the solution.

Adeno-, entero-, and reoviruses may be isolated from blood, urine, faeces, and post-mortem material; enteroviruses may be isolated from the cerebrospinal fluid.

Samples should he taken as early as possible after the onset of the disease. For the purpose of bleaching, they are centrifuged at 3000 X g for 30 min. The attendant bacterial flora is suppressed with penicillin and streptomycin (200-250 U/ml).

The material is stored by freezing at —30-70 °C.


The respiratory-syncytiai, corona-, reo-, and adenoviruses, one examines washings off the nasal portion of the throat and secretion of the mucous membrane of the posterior portion of the throat, which is removed with several cotton tampons. From one tampon impression smears are made, the remaining ones are immersed in 2-5 ml of Hanks' solution. To in­crease the resistance of paramyxoviruses, 0.5 per cent of gelatin or bovine albumin is added to the solution. rapiddiagnosis consists in detecting the virus antigen in the cells of the examined material, using such tests as IF, ELISA, HI HA, etc. Reoviruses escape detection by the rapid methods.

To isolate viruses, cultures of tissues of monkey kidneys and human embryo (paramyxo-, reo-, and adenoviruses), Hep-2, KB, and HeLa cultures (respiratory-syncytial virus), and organ cultures of the trachea and the lungs of human embryos (coronaviruses) are used.

The presence of the virus is determined by its cytopathic action, which is expressed in the formation of the syncytium (paramyxo-, respiratory-syncylial viruses), cessation and weakening of ciliary movements of the epithelial cells in organ cultures of the trachea (coronavirus), the appearance of granularity and cytoplasmic inclusions (reo- and adenoviruses).


The isolated viruses are identified, using specific immune sera with the help of the neutralization test in tissue cultures (paramyxoviruses, respiratory-syncytial, corona-, reo-, and adenoviruses), HadsI(paramyxo-, reoviruses), HAI (paramyxo-, reo, and adenoviruses), ELISA (paramyxoviruses), CF (all the above mentioned viruses), IF (respiralory-syncytial and reoviruses), as well as by means of intraracerebral infection of suckling mice (coronaviruses).


Serological examination sera with the help of the allows the diagnosis to he made upon the isolation of specific antibodies in the patients' serum. To set up serological reactions, paired sera are used, which are taken in the first days of the disease and then 1-2-3 weeks later and are studied simultaneously. Of diagnostic importance is a four-fold or greater increase in the titre of antibodies revealed by the HAI, N;, CF, Hadsl, IF, RIA, and ELISA tests with antigens (diagnosticums) prepared from reference strains of the appropriate viruses.


Treatment

Treatment sera with the help of the

Supportive

Fluids, oxygen, respiratory support, bronchodilators

Antiviral Agents

Ribavirin (Virazole), a synthetic guanosine analogue, given as an aerosol


Preventing spread
Preventing Spread sera with the help of the

  • Handwashing

  • Disinfection of surfaces

  • Gloves, masks, goggles, gowns

  • Isolation, and cohort nursing

  • Immunization


Prevention of disease

Prevention of Disease sera with the help of the

Active Immunization

Formalin inactivated vaccine resulted in enhanced disease

Subunit vaccines being studied


Prevention of disease1

Prevention of Disease sera with the help of the

Passive immunization (immunoprophylaxis)

Pooled hyperimmune globulin (RespiGam)

Monoclonal antibody to F protein- Palivizumab (Synagis)


ad